Tang Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Tang Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-70,000	Closed	-$8.82M	–	103
2023 Q4	$8.82M	Buy	70,000 +60,000	+600%	+$5.98M	0.81%	33
2023 Q3	$936K	Hold	10,000	–	–	0.13%	87
2023 Q2	$893K	Buy	+10,000	New	+$870K	0.13%	83
2023 Q1	–	Sell	-36,090	Closed	-$4.41M	–	105
2022 Q4	$4.41M	Sell	36,090 -30,000	-45%	-$3.48M	0.64%	39
2022 Q3	$6.82M	Buy	+66,090	New	+$6.27M	0.84%	37

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Tang Capital Management's ASND Position: Q1 2024 in Review

Tang Capital Management sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 70,000 shares — an estimated $8.82M sold.

Tang Capital Management first reported a position in ASND in Q3 2022 and held it in 5 quarters. The position peaked at $8.82M in Q4 2023. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

Tang Capital Management reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
Tang Capital Management sold 70,000 Ascendis Pharma A/S shares in Q1 2024, an estimated $8.82M.
Tang Capital Management first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 5 quarters.
Tang Capital Management's Ascendis Pharma A/S position peaked at $8.82M in Q4 2023.
189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.